ALKERMES | ALKS - Ordinary Share Capital


ALKERMES reported $167.54M in Ordinary Share Capital for its fiscal quarter ending in June of 2026.





Ordinary Share Capital Change Date
AbbVie USD 1.77B 1.75B Jun/2025
Acadia Pharmaceuticals USD 171.09M 1.9M Mar/2026
ALKERMES USD 167.54M 1.08M Jun/2026
Amgen USD 541M 1000K Jun/2026
Biogen USD 146.7M 200K Sep/2025
BioMarin Pharmaceutical USD 193.54M 267K Jun/2026
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Coherus Biosciences USD 121.16M 4.92M Dec/2025
Eli Lilly USD 943.5M 3.33M Mar/2026
Gilead Sciences USD 1.24B 1000K Jun/2026
Heron Therapeutics USD 188.31M 4.99M Dec/2025
Ionis Pharmaceuticals USD 165.64M 265K Jun/2026
J&J USD 2.41B 1.35M Mar/2026
Malin Corporation EUR 200K 0 Dec/2024
Merck USD 2.47B 4.93M Mar/2026
Minerva Neurosciences USD 1000 0 Sep/2024
Nektar Therapeutics USD 29.47M 9.09M Mar/2026
Neurocrine Biosciences USD 100.55M 50K Jun/2026
Otsuka Holdings JPY 525.39M 1.91M Jun/2026
Ovoca Bio EUR 29.49M 0 Dec/2025
Pfizer USD 5.7B 0 Jun/2026
Regeneron Pharmaceuticals USD 105M 300K Mar/2026
Vertex Pharmaceuticals USD 253.3M 900K Jun/2026